Skip to main content

Market Overview

Seagen's TUKYSA Wins European Approval For Metastatic Breast Cancer

  • The European Commission (EC) has granted marketing authorization to Seagen Inc's (NASDAQ: SGEN) TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, to treat adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
  • TUKYSA is an oral, small-molecule tyrosine kinase inhibitor of HER2, a protein that contributes to cancer cell growth.
  • The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for TUKYSA in December last year.
  • Price Action: SGEN stock slips 0.07% at $171.9 in premarket trading hours on the last check Friday.

Related Articles (SGEN)

View Comments and Join the Discussion!

Posted-In: breast cancer European CommissionBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at